Switching PARP inhibitors as an effective approach for niraparib-induced erythema multiforme

Int J Dermatol. 2022 Oct;61(10):e407-e408. doi: 10.1111/ijd.16055. Epub 2022 Jan 26.

Authors

David Pesqué^#¹, Sara Tormo-Mainar^#¹, Rafael Bach², Jordi Recuero-Borau², Ramon M Pujol¹

Affiliations

¹ Department of Dermatology, Hospital del Mar- Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
² Department of Oncology, Hospital del Mar- Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

^# Contributed equally.

PMID: 35080014
DOI: 10.1111/ijd.16055

No abstract available

Publication types

Letter

MeSH terms

Erythema Multiforme* / chemically induced
Erythema Multiforme* / drug therapy
Humans
Indazoles / adverse effects
Piperidines / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors* / adverse effects

Substances

Indazoles
Piperidines
Poly(ADP-ribose) Polymerase Inhibitors
niraparib